PHP Code

Using the PHP code extracts allows Academic Staff Profiles to be displayed in a number of different styles including the tabbed format shown below - the data is provided dynamically from the IRIS application, while maintaning the consistent look and feel of your site.

Prof John Hardy

Summary

John Hardy is the Chair of Molecular Biology of Neurological Disease at the UCL Institute of Neurology. With over 23,000 citations, Prof Hardy is the most cited Alzheimer's disease researcher in the UK (5th internationally). In recognition of his exceptional contributions to science, he was elected a Fellow of the Royal Society in 2009.

Research Summary

My research interests are in the genetic analysis of disease. Historically, we have worked on the genetic analysis of Alzheimer's disease and other dementias. More recently, we have worked on Parkinson's disease and other movement disorders and, most recently on motor neuron disease. Our early studies were on mendelian forms of disease and these studies continue, but an increasing focus has been on the genetic analysis of complex traits related to disease. Additionally, this latter analysis has made us increasingly interested in population genetics because the risk variants for human traits are likely to be different in different racial groups.
In all cases our intention is to develop an understanding of the underlying genetics of a disorder so we can work with those making cellular and animal models of the disease to help, both in the unerstanding of disease mechanisms and to help in the search for treatements. In this regard, we therefore have three types of collaborations: collaborations with clinicians who treat patients with disease, especially colleagues at the Institute of Neurology, but also elsewhere, collaborations with other geneticists to collaboratively analyse such patient material, and collaborations with cell biologists and transgenic mice people to eneble them to build good models of disease.

Research Activities

  • A systematic investigation into the pathogenesis and course of Parkinson's syndrome
  • Cellular mechanisms underlying neurodegeneration
  • Clinical, genetic and cell biology studies of hereditary movement disorders: dystonia, Huntington’s disease, Hereditary spastic paraplegia
  • Genetic studies of neurological disease
  • Inflammatory conditions of the gastrointestinal tract
  • Neurological disease
  • Neuromuscular and Neurodegenerative Disorders
  • Parkinsons disease and related Movement Disorders
  • The neurogenetics of neurodegenerative disease
  • population genetics

Recent Publications

Displaying 50 most recent publications. For the full list please visit UCL Discovery

  1. Doherty KM,Hardy J (2013) Parkin disease and the Lewy body conundrum. Mov Disord. 10.1002/mds.25486.
  2. Tucci A,Kara E,Schossig A,Wolf NI,Plagnol V,Fawcett K,Paisán-Ruiz C,Moore M,Hernandez D,Musumeci S,Tennison M,Hennekam R,Palmeri S,Malandrini A,Raskin S,Donnai D,Hennig C,Tzschach A,Hordijk R,Bast T,Wimmer K,Lo CN,Shorvon S,Mefford H,Eichler EE,Hall R,Hayes I,Hardy J,Singleton A,Zschocke J,Houlden H (2013) Kohlschütter-Tönz syndrome: mutations in ROGDI and evidence of genetic heterogeneity. Hum Mutat, 34(2), 296 - 300. 10.1002/humu.22241.
  3. Kara E,Lewis PA,Ling H,Proukakis C,Houlden H,Hardy J (2013) α-Synuclein mutations cluster around a putative protein loop. Neurosci Lett. 10.1016/j.neulet.2013.04.058.
  4. Ling H,Kara E,Bandopadhyay R,Hardy J,Holton J,Xiromerisiou G,Lees A,Houlden H,Revesz T (2013) TDP-43 pathology in a patient carrying G2019S LRRK2 mutation and a novel p.Q124E MAPT Neurobiology of Aging.
  5. Beck J,Poulter M,Hensman D,Rohrer JD,Mahoney CJ,Adamson G,Campbell T,Uphill J,Borg A,Fratta P,Orrell RW,Malaspina A,Rowe J,Brown J,Hodges J,Sidle K,Polke JM,Houlden H,Schott JM,Fox NC,Rossor MN,Tabrizi SJ,Isaacs AM,Hardy J,Warren JD,Collinge J,Mead S (2013) Large C9orf72 hexanucleotide repeat expansions are seen in multiple neurodegenerative syndromes and are more frequent than expected in the UK population American Journal of Human Genetics, 92(3), 345 - 353.
  6. Hardy J (2013) Reply to Letter: Identical twins with leucine rich repeat kinase type 2 mutations discordant for Parkinson's disease Movement Disorders, 28(4), 561 - 562.
  7. Mok K,Laaksovirta H,Tienari PJ,Peuralinna T,Myllykangas L,Chiò A,Traynor BJ,Nalls MA,Gurunlian N,Shatunov A,Restagno G,Mora G,Nigel Leigh P,Shaw CE,Morrison KE,Shaw PJ,Al-Chalabi A,Hardy J,Orrell RW (2013) Homozygosity analysis in amyotrophic lateral sclerosis. Eur J Hum Genet. 10.1038/ejhg.2013.59.
  8. Doherty KM,Silveira-Moriyama L,Parkkinen L,Healy DG,Farrell M,Mencacci NE,Ahmed Z,Brett FM,Hardy J,Quinn N,Counihan TJ,Lynch T,Fox ZV,Revesz T,Lees AJ,Holton JL (2013) Parkin disease - a clinicopathological entity? NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 39, 11 - 12.
  9. Kiely AP,Asi YT,Kara E,Limousin P,Ling H,Lewis P,Proukakis C,Quinn N,Lees AJ,Hardy J,Revesz T,Houlden H,Holton JL (2013) Synucleinopathy with a G51D a-synuclein mutation: a neuropathological and genetic study NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 39, 39 - 40.
  10. Bartolome F,Wu H-C,Burchell VS,Preza E,Wray S,Mahoney CJ,Fox NC,Calvo A,Canosa A,Moglia C,Mandrioli J,Chiò A,Orrell RW,Houlden H,Hardy J,Abramov AY,Plun-Favreau H (2013) Pathogenic VCP Mutations Induce Mitochondrial Uncoupling and Reduced ATP Levels Neuron, 78(1), 57 - 64.
  11. Khan TA,Shah T,Prieto D,Zhang W,Price J,Fowkes GR,Cooper J,Talmud PJ,Humphries SE,Sundstrom J,Hubacek JA,Ebrahim S,Lawlor DA,Ben-Shlomo Y,Abdollahi MR,Slooter AJ,Szolnoki Z,Sandhu M,Wareham N,Frikke-Schmidt R,Tybjærg-Hansen A,Fillenbaum G,Heijmans BT,Katsuya T,Gromadzka G,Singleton A,Ferrucci L,Hardy J,Worrall B,Rich SS,Matarin M,Whittaker J,Gaunt TR,Whincup P,Morris R,Deanfield J,Donald A,Davey Smith G,Kivimaki M,Kumari M,Smeeth L,Khaw KT,Nalls M,Meschia J,Sun K,Hui R,Day I,Hingorani AD,Casas JP (2013) Apolipoprotein E genotype, cardiovascular biomarkers and risk of stroke: systematic review and meta-analysis of 14,015 stroke cases and pooled analysis of primary biomarker data from up to 60,883 individuals. Int J Epidemiol, 42(2), 475 - 492. 10.1093/ije/dyt034.
  12. Bartolome F,Wu HC,Burchell VS,Preza E,Wray S,Mahoney CJ,Fox NC,Calvo A,Canosa A,Moglia C,Mandrioli J,Chiò A,Orrell RW,Houlden H,Hardy J,Abramov AY,Plun-Favreau H (2013) Pathogenic VCP Mutations Induce Mitochondrial Uncoupling and Reduced ATP Levels. Neuron, 78(1), 57 - 64. 10.1016/j.neuron.2013.02.028.
  13. Schneider SA,Dusek P,Hardy J,Westenberger A,Jankovic J,Bhatia KP (2013) Genetics and Pathophysiology of Neurodegeneration with Brain Iron Accumulation (NBIA) CURRENT NEUROPHARMACOLOGY, 11(1), 59 - 79.
  14. Andreasson U,Lautner R,Schott JM,Mattsson N,Hansson O,Herukka SK,Helisalmi S,Ewers M,Hampel H,Wallin A,Minthon L,Hardy J,Blennow K,Zetterberg H (2013) CSF biomarkers for Alzheimer's pathology and the effect size of APOE ɛ4. Mol Psychiatry. 10.1038/mp.2013.18.
  15. Holton P,Ryten M,Nalls M,Trabzuni D,Weale ME,Hernandez D,Crehan H,Gibbs JR,Mayeux R,Haines JL,Farrer LA,Pericak-Vance MA,Schellenberg GD,Ramirez-Restrepo M,Engel A,Myers AJ,Corneveaux JJ,Huentelman MJ,Dillman A,Cookson MR,Reiman EM,Singleton A,Hardy J,Guerreiro R (2013) Initial Assessment of the Pathogenic Mechanisms of the Recently Identified Alzheimer Risk Loci Annals of Human Genetics, 77(2), 85 - 105.
  16. Xiromerisiou G,Dardiotis E,Tsironi EE,Hadjigeorgiou G,Ralli S,Kara E,Petalas A,Tachmitzi S,Hardy J,Houlden H (2013) THAP1 mutations in a Greek primary blepharospasm series Parkinsonism and Related Disorders, 19(3), 404 - 405.
  17. Ramasamy A,Trabzuni D,Gibbs JR,Dillman A,Hernandez DG,Arepalli S,Walker R,Smith C,Ilori GP,Shabalin AA,Li Y,Singleton AB,Cookson MR,for NABEC ,Hardy J,for UKBEC ,Ryten M,Weale ME (2013) Resolving the polymorphism-in-probe problem is critical for correct interpretation of expression QTL studies. Nucleic Acids Res, 41(7), e88. 10.1093/nar/gkt069.
  18. Lashley T,Hardy J,Isaacs AM (2013) RANTing about C9orf72. Neuron, 77(4), 597 - 598. 10.1016/j.neuron.2013.02.009.
  19. Crehan H,Hardy J,Pocock J (2013) Blockage of CR1 prevents activation of rodent microglia. Neurobiol Dis, 54, 139 - 149. 10.1016/j.nbd.2013.02.003.
  20. Beck J,Poulter M,Hensman D,Rohrer JD,Mahoney CJ,Adamson G,Campbell T,Uphill J,Borg A,Fratta P,Orrell RW,Malaspina A,Rowe J,Brown J,Hodges J,Sidle K,Polke JM,Houlden H,Schott JM,Fox NC,Rossor MN,Tabrizi SJ,Isaacs AM,Hardy J,Warren JD,Collinge J,Mead S (2013) Large C9orf72 hexanucleotide repeat expansions are seen in multiple neurodegenerative syndromes and are more frequent than expected in the UK population. Am J Hum Genet, 92(3), 345 - 353. 10.1016/j.ajhg.2013.01.011.
  21. Duran R,Mencacci NE,Angeli AV,Shoai M,Deas E,Houlden H,Mehta A,Hughes D,Cox TM,Deegan P,Schapira AH,Lees AJ,Limousin P,Jarman PR,Bhatia KP,Wood NW,Hardy J,Foltynie T (2013) The glucocerobrosidase E326K variant predisposes to Parkinson's disease, but does not cause Gaucher's disease Movement Disorders, 28(2), 232 - 236.
  22. Klebe S,Golmard JL,Nalls MA,Saad M,Singleton AB,Bras JM,Hardy J,Simon-Sanchez J,Heutink P,Kuhlenbäumer G,Charfi R,Klein C,Hagenah J,Gasser T,Wurster I,Lesage S,Lorenz D,Deuschl G,Durif F,Pollak P,Damier P,Tison F,Durr A,Amouyel P,Lambert JC,Tzourio C,Maubaret C,Charbonnier-Beaupel F,Tahiri K,Vidailhet M,Martinez M,Brice A,Corvol JC,French Parkinson's Disease Genetics Study Group and the International Parkinson's Disease Genomics Consortium (IPDGC) (2013) The Val158Met COMT polymorphism is a modifier of the age at onset in Parkinson's disease with a sexual dimorphism. J Neurol Neurosurg Psychiatry, 84(6), 666 - 673. 10.1136/jnnp-2012-304475.
  23. Holmans P,Moskvina V,Jones L,Sharma M,International Parkinson's Disease Genomics Consortium ,Vedernikov A,Buchel F,Sadd M,Bras JM,Bettella F,Nicolaou N,Simón-Sánchez J,Mittag F,Gibbs JR,Schulte C,Durr A,Guerreiro R,Hernandez D,Brice A,Stefánsson H,Majamaa K,Gasser T,Heutink P,Wood NW,Martinez M,Singleton AB,Nalls MA,Hardy J,Morris HR,Williams NM (2013) A pathway-based analysis provides additional support for an immune-related genetic susceptibility to Parkinson's disease. Hum Mol Genet, 22(5), 1039 - 1049. 10.1093/hmg/dds492.
  24. Kiely AP,Asi YT,Kara E,Limousin P,Ling H,Lewis P,Proukakis C,Quinn N,Lees AJ,Hardy J,Revesz T,Houlden H,Holton JL (2013) α-Synucleinopathy associated with G51D SNCA mutation: a link between Parkinson's disease and multiple system atrophy? Acta Neuropathologica, 1 - 17.
  25. Guerreiro RJ,Lohmann E,Brás JM,Gibbs JR,Rohrer JD,Gurunlian N,Dursun B,Bilgic B,Hanagasi H,Gurvit H,Emre M,Singleton A,Hardy J (2013) Using exome sequencing to reveal mutations in TREM2 presenting as a frontotemporal dementia-like syndrome without bone involvement. JAMA Neurol, 70(1), 78 - 84. 10.1001/jamaneurol.2013.579.
  26. Tucci A,Kara E,Schossig A,Wolf NI,Plagnol V,Fawcett K,Paisán-Ruiz C,Moore M,Hernandez D,Musumeci S,Tennison M,Hennekam R,Palmeri S,Malandrini A,Raskin S,Donnai D,Hennig C,Tzschach A,Hordijk R,Bast T,Wimmer K,Lo C-N,Shorvon S,Mefford H,Eichler EE,Hall R,Hayes I,Hardy J,Singleton A,Zschocke J,Houlden H (2013) Kohlschütter-Tönz Syndrome: Mutations in ROGDI and Evidence of Genetic Heterogeneity Human Mutation, 34(2), 296 - 300.
  27. Holton P,Ryten M,Nalls M,Trabzuni D,Weale ME,Hernandez D,Crehan H,Gibbs JR,Mayeux R,Haines JL,Farrer LA,Pericak-Vance MA,Schellenberg GD,Alzheimer's Disease Genetics Consortium ,Ramirez-Restrepo M,Engel A,Myers AJ,Corneveaux JJ,Huentelman MJ,Dillman A,Cookson MR,Reiman EM,Singleton A,Hardy J,Guerreiro R,Apostolova LG,Arnold SE,Baldwin CT,Barber R,Barmada MM,Beach TG,Beecham GW,Beekly D,Bennett DA,Bigio EH,Bird TD,Blacker D,Boeve BF,Bowen JD,Boxer A,Burke JR,Buros J,Buxbaum JD,Cairns NJ,Cantwell LB,Cao C,Carlson CS,Carney RM,Carrasquillo MM,Carroll SL,Chui HC,Clark DG,Cotman CW,Crane PK,Crocco EA,Cruchaga C,Cummings JL,De Jager PL,DeCarli C,DeKosky ST,Demirci FY,Diaz-Arrastia R,Dick M,Dickson DW,Duara R,Ellis WG,Ertekin-Taner N,Evans D,Faber KM,Fallon KB,Farlow MR,Ferris S,Foroud TM,Frosch MP,Galasko DR,Ganguli M,Gearing M,Geschwind DH,Ghetti B,Gilbert JR,Gilman S,Giordani B,Glass JD,Goate AM,Graff-Radford NR,Green RC,Growdon JH,Hakonarson H,Hamilton RL,Harrell LE,Head E,Honig LS,Hulette CM,Hyman BT,Jarvik GP,Jicha GA,Jin LW,Jun G,Kamboh MI,Karlawish J,Karydas A,Kauwe JS,Kaye JA,Kim R,Koo EH,Kowall NW,Kramer P,Kukull WA,Lah JJ,Larson EB,Levey AI,Lieberman AP,Lopez OL,Lunetta KL,Mack WJ,Marson DC,Martin ER,Martiniuk F,Mash DC,Masliah E,McCormick WC,McCurry SM,McDavid AN,McKee AC,Mesulam M,Miller BL,Miller CA,Miller JW,Montine TJ,Morris JC,Naj AC,Nowotny P,Parisi JE,Peskind E,Petersen RC,Poon WW,Potter H,Quinn JF,Raj A,Rajbhandary RA,Raskind M,Reisberg B,Reitz C,Ringman JM,Roberson ED,Rogaeva E,Rosenberg RN,Sano M,Saykin AJ,Schneider JA,Schneider LS,Seeley WW,Shelanski ML,Smith CD,Sonnen JA,Spina S,St George-Hyslop P,Stern RA,Tanzi RE,Trojanowski JQ,Troncoso JC,Tsuang DW,Valladares O,Van Deerlin VM,Vardarajan BN,Vinters HV,Vonsattel JP,Wang LS,Weintraub S,Welsh-Bohmer KA,Williamson J,Woltjer RL,Wright CB,Younkin SG (2013) Initial assessment of the pathogenic mechanisms of the recently identified Alzheimer risk Loci. Ann Hum Genet, 77(2), 85 - 105. 10.1111/ahg.12000.
  28. Kumar A,Gibbs JR,Beilina A,Dillman A,Kumaran R,Trabzuni D,Ryten M,Walker R,Smith C,Traynor BJ,Hardy J,Singleton AB,Cookson MR (2013) Age-associated changes in gene expression in human brain and isolated neurons Neurobiology of Aging, 34(4), 1199 - 1209.
  29. Guerreiro R,Wojtas A,Bras J,Carrasquillo M,Rogaeva E,Majounie E,Cruchaga C,Sassi C,Kauwe JS,Younkin S,Hazrati L,Collinge J,Pocock J,Lashley T,Williams J,Lambert JC,Amouyel P,Goate A,Rademakers R,Morgan K,Powell J,St George-Hyslop P,Singleton A,Hardy J,Alzheimer Genetic Analysis Group (2013) TREM2 variants in Alzheimer's disease. N Engl J Med, 368(2), 117 - 127. 10.1056/NEJMoa1211851.
  30. Kumar A,Gibbs JR,Beilina A,Dillman A,Kumaran R,Trabzuni D,Ryten M,Walker R,Smith C,Traynor BJ,Hardy J,Singleton AB,Cookson MR (2013) Age-associated changes in gene expression in human brain and isolated neurons. Neurobiol Aging, 34(4), 1199 - 1209. 10.1016/j.neurobiolaging.2012.10.021.
  31. Cleeter MW,Chau KY,Gluck C,Mehta A,Hughes DA,Duchen M,Wood NW,Hardy J,Mark Cooper J,Schapira AH (2013) Glucocerebrosidase inhibition causes mitochondrial dysfunction and free radical damage. Neurochem Int, 62(1), 1 - 7. 10.1016/j.neuint.2012.10.010.
  32. Xiromerisiou G,Dardiotis E,Tsironi EE,Hadjigeorgiou G,Ralli S,Kara E,Petalas A,Tachmitzi S,Hardy J,Houlden H (2013) THAP1 mutations in a Greek primary blepharospasm series. Parkinsonism Relat Disord, 19(3), 404 - 405. 10.1016/j.parkreldis.2012.08.015.
  33. Hudson G,Nalls M,Evans JR,Breen DP,Winder-Rhodes S,Morrison KE,Morris HR,Williams-Gray CH,Barker RA,Singleton AB,Hardy J,Wood NE,Burn DJ,Chinnery PF (2013) Two-stage association study and meta-analysis of mitochondrial DNA variants in Parkinson disease. Neurology. 10.1212/WNL.0b013e318294b434.
  34. Majounie E,Abramzon Y,Renton AE,Perry R,Bassett SS,Pletnikova O,Troncoso JC,Hardy J,Singleton AB,Traynor BJ (2012) Repeat Expansion in C9ORF72 in Alzheimer's Disease NEW ENGLAND JOURNAL OF MEDICINE, 366(3), 283 - 284. 10.1056/NEJMc1113592.
  35. Ferrari R,Mok K,Moreno JH,Cosentino S,Goldman J,Pietrini P,Mayeux R,Tierney MC,Kapogiannis D,Jicha GA,Murrell JR,Ghetti B,Wassermann EM,Grafman J,Hardy J,Huey ED,Momeni P (2012) Screening for C9ORF72 repeat expansion in FTLD Neurobiology of Aging, 33(8), e1 - e11.
  36. Ferrari R,Mok K,Moreno JH,Cosentino S,Goldman J,Pietrini P,Mayeux R,Tierney MC,Kapogiannis D,Jicha GA,Murrell JR,Ghetti B,Wassermann EM,Grafman J,Hardy J,Huey ED,Momeni P (2012) Screening for C9ORF72 repeat expansion in FTLD. Neurobiol Aging, 33(8), 1850.e1 - 1850.11. 10.1016/j.neurobiolaging.2012.02.017.
  37. Tucci A,Charlesworth G,Sheerin U-M,Plagnol V,Wood NW,Hardy J (2012) Study of the genetic variability in a Parkinson's Disease gene: EIF4G1 Neuroscience Letters, 518(1), 19 - 22.
  38. Tucci A,Charlesworth G,Sheerin UM,Plagnol V,Wood NW,Hardy J (2012) Study of the genetic variability in a Parkinson's Disease gene: EIF4G1. Neurosci Lett, 518(1), 19 - 22. 10.1016/j.neulet.2012.04.033.
  39. Schneider SA,Hardy J,Bhatia KP (2012) Syndromes of neurodegeneration with brain iron accumulation (NBIA): an update on clinical presentations, histological and genetic underpinnings, and treatment considerations. Mov Disord, 27(1), 42 - 53. 10.1002/mds.23971.
  40. Charlesworth G,Gandhi S,Bras JM,Barker RA,Burn DJ,Chinnery PF,Gentleman SM,Guerreiro R,Hardy J,Holton JL,Lees A,Morrison K,Sheerin U-M,Williams N,Morris H,Revesz T,Wood NW (2012) Tau acts as an independent genetic risk factor in pathologically proven PD Neurobiology of Aging, 33(4), 838.e7 - 838.e11.
  41. Charlesworth G,Gandhi S,Bras JM,Barker RA,Burn DJ,Chinnery PF,Gentleman SM,Guerreiro R,Hardy J,Holton JL,Lees A,Morrison K,Sheerin UM,Williams N,Morris H,Revesz T,Wood NW (2012) Tau acts as an independent genetic risk factor in pathologically proven PD. Neurobiol Aging, 33(4), 838.e7 - 838.11. 10.1016/j.neurobiolaging.2011.11.001.
  42. Xiromerisiou G,Houlden H,Scarmeas N,Stamelou M,Kara E,Hardy J,Lees AJ,Korlipara P,Limousin P,Paudel R,Hadjigeorgiou GM,Bhatia KP (2012) THAP1 mutations and dystonia phenotypes: genotype phenotype correlations. Mov Disord, 27(10), 1290 - 1294. 10.1002/mds.25146.
  43. Guerreiro RJ,Gustafson DR,Hardy J (2012) The genetic architecture of Alzheimer's disease: beyond APP, PSENs and APOE. Neurobiol Aging, 33(3), 437 - 456. 10.1016/j.neurobiolaging.2010.03.025.
  44. Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium ,Hingorani AD,Casas JP (2012) The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet, 379(9822), 1214 - 1224. 10.1016/S0140-6736(12)60110-X.
  45. Kara E,Ling H,Pittman AM,Shaw K,de Silva R,Simone R,Holton JL,Warren JD,Rohrer JD,Xiromerisiou G,Lees A,Hardy J,Houlden H,Revesz T (2012) The MAPT p.A152T variant is a risk factor associated with tauopathies with atypical clinical and neuropathological features Neurobiology of Aging.
  46. Kara E,Ling H,Pittman AM,Shaw K,de Silva R,Simone R,Holton JL,Warren JD,Rohrer JD,Xiromerisiou G,Lees A,Hardy J,Houlden H,Revesz T (2012) The MAPT p.A152T variant is a risk factor associated with tauopathies with atypical clinical and neuropathological features Neurobiology of Aging, 33(9), 2231e7 - 2231e14.
  47. Gerrish A,Russo G,Richards A,Moskvina V,Ivanov D,Harold D,Sims R,Abraham R,Hollingworth P,Chapman J,Hamshere M,Pahwa JS,Dowzell K,Williams A,Jones N,Thomas C,Stretton A,Morgan AR,Lovestone S,Powell J,Proitsi P,Lupton MK,Brayne C,Rubinsztein DC,Gill M,Lawlor B,Lynch A,Morgan K,Brown KS,Passmore PA,Craig D,McGuinness B,Todd S,Johnston JA,Holmes C,Mann D,Smith AD,Love S,Kehoe PG,Hardy J,Mead S,Fox N,Rossor M,Collinge J,Maier W,Jessen F,Kölsch H,Heun R,Schürmann B,Bussche HVD,Heuser I,Kornhuber J,Wiltfang J,Dichgans M,Frölich L,Hampel H,Hüll M,Rujescu D,Goate AM,Kauwe JSK,Cruchaga C,Nowotny P,Morris JC,Mayo K,Livingston G,Bass NJ,Gurling H,McQuillin A,Gwilliam R,Deloukas P,Davies G,Harris SE,Starr JM,Deary IJ,Al-Chalabi A,Shaw CE,Tsolaki M,Singleton AB,Guerreiro R,Mühleisen TW,Nöthen MM,Moebus S,Jöckel K-H,Klopp N,Wichmann H-E,Carrasquillo MM,Pankratz VS,Younkin SG,Jones L,Holmans PA,O'Donovan MC,Owen MJ,Williams J (2012) The role of variation at AβPP, PSEN1, PSEN2, and MAPT in late onset Alzheimer's disease Journal of Alzheimer's Disease, 28(2), 377 - 387.
  48. Gerrish A,Russo G,Richards A,Moskvina V,Ivanov D,Harold D,Sims R,Abraham R,Hollingworth P,Chapman J,Hamshere M,Pahwa JS,Dowzell K,Williams A,Jones N,Thomas C,Stretton A,Morgan AR,Lovestone S,Powell J,Proitsi P,Lupton MK,Brayne C,Rubinsztein DC,Gill M,Lawlor B,Lynch A,Morgan K,Brown KS,Passmore PA,Craig D,McGuinness B,Todd S,Johnston JA,Holmes C,Mann D,Smith AD,Love S,Kehoe PG,Hardy J,Mead S,Fox N,Rossor M,Collinge J,Maier W,Jessen F,Kölsch H,Heun R,Schürmann B,van den Bussche H,Heuser I,Kornhuber J,Wiltfang J,Dichgans M,Frölich L,Hampel H,Hüll M,Rujescu D,Goate AM,Kauwe JS,Cruchaga C,Nowotny P,Morris JC,Mayo K,Livingston G,Bass NJ,Gurling H,McQuillin A,Gwilliam R,Deloukas P,Davies G,Harris SE,Starr JM,Deary IJ,Al-Chalabi A,Shaw CE,Tsolaki M,Singleton AB,Guerreiro R,Mühleisen TW,Nöthen MM,Moebus S,Jöckel KH,Klopp N,Wichmann HE,Carrasquillo MM,Pankratz VS,Younkin SG,Jones L,Holmans PA,O'Donovan MC,Owen MJ,Williams J (2012) The role of variation at AβPP, PSEN1, PSEN2, and MAPT in late onset Alzheimer's disease. J Alzheimers Dis, 28(2), 377 - 387. 10.3233/JAD-2011-110824.
  49. Hardy J,Revesz T (2012) The spread of neurodegenerative disease. N Engl J Med, 366(22), 2126 - 2128. 10.1056/NEJMcibr1202401.
  50. Goate A,Hardy J (2012) Twenty years of Alzheimer's disease-causing mutations. J Neurochem, 120 Suppl 1, 3 - 8. 10.1111/j.1471-4159.2011.07575.x.

Biography

John Hardy is the Chair of Molecular Biology of Neurological Disease at the UCL Institute of Neurology. With over 23,000 citations, Prof Hardy is the most cited Alzheimer's disease researcher in the UK (5th internationally). In recognition of his exceptional contributions to science, he was elected a Fellow of the Royal Society in 2009.

Qualifications

  • 1981: Doctor of Philosophy, Imperial College of Science, Technology and Medicine
  • 1976: Bachelor of Science, University of Leeds